Completed PHASE4 INTERVENTIONAL NCT00347841
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
Sponsor: Innovative Medical
Conditions
Glaucoma
Interventions
Bimatoprost 0.03%, Latanoprost
Updated 5 times since 2017 Last updated: May 30, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE4 trial investigates Glaucoma and is currently completed. Innovative Medical leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Innovative Medical
Data source: Innovative Medical
For direct contact, visit the study record on ClinicalTrials.gov .